Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock (CYCCP)

6.11
NASDAQ
Prev Close 6.11
Day Low/High 0.00 / 0.00
52 Wk Low/High 5.05 / 9.05
Exchange NASDAQ
Shares Outstanding 335.00M
Market Cap 2.05M
Div & Yield N.A. (N.A)

Latest News

Cash Dividend On The Way From Cyclacel Pharmaceuticals Convertible Exchangeable Preferred Stock

Cash Dividend On The Way From Cyclacel Pharmaceuticals Convertible Exchangeable Preferred Stock

On 7/12/17, Cyclacel Pharmaceuticals, Inc's 6% Convertible Exchangeable Preferred Stock will trade ex-dividend, for its quarterly dividend of $0.15, payable on 8/1/17. As a percentage of CYCCP's recent share price of $6.69, this dividend works out to approximately 2.24%, so look for shares of CYCCP to trade 2.24% lower — all else being equal — when CYCCP shares open for trading on 7/12/17.

Cyclacel Pharmaceuticals' 6% Preferred Stock Shares Cross 9.5% Yield Mark

In trading on Tuesday, shares of Cyclacel Pharmaceuticals, Inc's 6% Convertible Exchangeable Preferred Stock were yielding above the 9.5% mark based on its quarterly dividend (annualized to $0.60), with shares changing hands as low as $6.25 on the day. This compares to an average yield of 10.60% in the "Biotechnology" preferred stock category, according to Preferred Stock Channel.

Cyclacel Pharmaceuticals Reports First Quarter 2017 Financial Results

Conference Call Scheduled May 11, 2017 at 4:30 p.m. EDT

Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2016 Financial Results

Conference Call Scheduled March 28, 2017 at 4:30 p.m. EDT

Cyclacel's CDK Inhibitor CYC065 Causes Anaphase Catastrophe, A Novel Cancer-Specific Mechanism Of Action, In Research Published In JNCI

CYC065 found effective against lung cancer cell lines including those with KRAS mutations

Cyclacel Pharmaceuticals' Preferred Stock Shares Cross 9% Yield Mark

In trading on Tuesday, shares of Cyclacel Pharmaceuticals, Inc's 6% Convertible Exchangeable Preferred Stock were yielding above the 9% mark based on its quarterly dividend (annualized to $0.60), with shares changing hands as low as $6.58 on the day. This compares to an average yield of 10.81% in the "Biotechnology" preferred stock category, according to Preferred Stock Channel.

Cyclacel's Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Potential In Esophageal Cancer And Acute Leukemia

Cyclacel's Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Potential In Esophageal Cancer And Acute Leukemia

-Preclinical Data Presented at the 28th EORTC-NCI-AACR Symposium-

Cyclacel Pharmaceuticals Reports 3rd Quarter 2016 Financial Results

Cyclacel Pharmaceuticals Reports 3rd Quarter 2016 Financial Results

Conference Call Scheduled for November 14, 2016 at 4:30 p.m. ET

Cyclacel Pharmaceuticals's Preferred Stock Shares Cross 9% Yield Mark

Cyclacel Pharmaceuticals's Preferred Stock Shares Cross 9% Yield Mark

In trading on Tuesday, shares of Cyclacel Pharmaceuticals, Inc's 6% Convertible Exchangeable Preferred Stock were yielding above the 9% mark based on its quarterly dividend (annualized to $0.60), with shares changing hands as low as $6.51 on the day. This compares to an average yield of 10.90% in the "Biotechnology" preferred stock category, according to Preferred Stock Channel.

Cyclacel's CYC065 Demonstrates Promising Activity In MYCN-Addicted Neuroblastoma In Preclinical Data Presented At Childhood Cancer 2016

Cyclacel's CYC065 Demonstrates Promising Activity In MYCN-Addicted Neuroblastoma In Preclinical Data Presented At Childhood Cancer 2016

Data support CYC065 as potential treatment for MYCN amplified/overexpressed neuroblastoma

Cyclacel Pharmaceuticals Reports 2nd Quarter 2016 Financial Results

Cyclacel Pharmaceuticals Reports 2nd Quarter 2016 Financial Results

Conference Call Scheduled August 10, 2016 at 4:30 p.m. EDT

Cyclacel Reports Updated Data From Its DNA Damage Response Program On Seliciclib And Sapacitabine Combination In Patients With Solid Tumors At ASCO

Cyclacel Reports Updated Data From Its DNA Damage Response Program On Seliciclib And Sapacitabine Combination In Patients With Solid Tumors At ASCO

Combination Showed 35.6% Disease Control Rate and Durable Responses including CR and PR in Heavily-Pretreated Patients with BRCA Mutations

Cyclacel Announces Reverse Stock Split

Cyclacel Announces Reverse Stock Split

Cyclacel Pharmaceuticals Reports First Quarter 2016 Financial Results

Cyclacel Pharmaceuticals Reports First Quarter 2016 Financial Results

Conference Call Scheduled May 11, 2016 at 4:30 p.m. EDT